Which has better earnings & valuation, TYRA or SION?

Tyra Biosciences is trading at a lower price-to-earnings ratio than Sionna Therapeutics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Tyra Biosciences N/A N/A -$119.95M -$2.40 N/A Sionna Therapeutics N/A N/A -$75.27M -$2.18 N/A

Is TYRA or SION more profitable?

Sionna Therapeutics' return on equity of -32.94% beat Tyra Biosciences' return on equity. Company Net Margins Return on Equity Return on Assets Tyra Biosciences N/A -46.39% -43.07% Sionna Therapeutics N/A -32.94% -31.08%

Does the media prefer TYRA or SION?

In the previous week, Sionna Therapeutics had 3 more articles in the media than Tyra Biosciences. MarketBeat recorded 14 mentions for Sionna Therapeutics and 11 mentions for Tyra Biosciences. Tyra Biosciences' average media sentiment score of 0.37 beat Sionna Therapeutics' score of 0.00 indicating that Tyra Biosciences is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Tyra Biosciences 2 Very Positive mention(s) 3 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Neutral Sionna Therapeutics 1 Very Positive mention(s) 2 Positive mention(s) 7 Neutral mention(s) 2 Negative mention(s) 1 Very Negative mention(s) Neutral

Which has stronger earnings and valuation, SION or ORIC?

Oric Pharmaceuticals is trading at a lower price-to-earnings ratio than Sionna Therapeutics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Sionna Therapeutics N/A N/A -$75.27M -$2.18 N/A Oric Pharmaceuticals N/A N/A -$129.47M -$1.35 N/A

Is SION or ORIC more profitable?

Sionna Therapeutics' return on equity of -32.94% beat Oric Pharmaceuticals' return on equity. Company Net Margins Return on Equity Return on Assets Sionna Therapeutics N/A -32.94% -31.08% Oric Pharmaceuticals N/A -35.35% -33.39%

Does the media favor SION or ORIC?

In the previous week, Sionna Therapeutics had 11 more articles in the media than Oric Pharmaceuticals. MarketBeat recorded 14 mentions for Sionna Therapeutics and 3 mentions for Oric Pharmaceuticals. Oric Pharmaceuticals' average media sentiment score of 0.37 beat Sionna Therapeutics' score of 0.00 indicating that Oric Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Sionna Therapeutics 1 Very Positive mention(s) 2 Positive mention(s) 7 Neutral mention(s) 2 Negative mention(s) 1 Very Negative mention(s) Neutral Oric Pharmaceuticals 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Neutral

Is SION or AKTS more profitable?

Aktis Oncology's return on equity of 0.00% beat Sionna Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Sionna Therapeutics N/A -32.94% -31.08% Aktis Oncology N/A N/A N/A

Does the media prefer SION or AKTS?

In the previous week, Sionna Therapeutics had 12 more articles in the media than Aktis Oncology. MarketBeat recorded 14 mentions for Sionna Therapeutics and 2 mentions for Aktis Oncology. Aktis Oncology's average media sentiment score of 0.86 beat Sionna Therapeutics' score of 0.00 indicating that Aktis Oncology is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Sionna Therapeutics 1 Very Positive mention(s) 2 Positive mention(s) 7 Neutral mention(s) 2 Negative mention(s) 1 Very Negative mention(s) Neutral Aktis Oncology 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media refer more to SION or MGTX?

In the previous week, Sionna Therapeutics had 12 more articles in the media than MeiraGTx. MarketBeat recorded 14 mentions for Sionna Therapeutics and 2 mentions for MeiraGTx. MeiraGTx's average media sentiment score of 0.83 beat Sionna Therapeutics' score of 0.00 indicating that MeiraGTx is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Sionna Therapeutics 1 Very Positive mention(s) 2 Positive mention(s) 7 Neutral mention(s) 2 Negative mention(s) 1 Very Negative mention(s) Neutral MeiraGTx 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Is ALMS or SION more profitable?

Sionna Therapeutics has a net margin of 0.00% compared to Alumis' net margin of -5,933.46%. Sionna Therapeutics' return on equity of -32.94% beat Alumis' return on equity. Company Net Margins Return on Equity Return on Assets Alumis -5,933.46% -93.15% -74.50% Sionna Therapeutics N/A -32.94% -31.08%

Does the media favor ALMS or SION?

In the previous week, Sionna Therapeutics had 8 more articles in the media than Alumis. MarketBeat recorded 14 mentions for Sionna Therapeutics and 6 mentions for Alumis. Alumis' average media sentiment score of 0.41 beat Sionna Therapeutics' score of 0.00 indicating that Alumis is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Alumis 1 Very Positive mention(s) 0 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Sionna Therapeutics 1 Very Positive mention(s) 2 Positive mention(s) 7 Neutral mention(s) 2 Negative mention(s) 1 Very Negative mention(s) Neutral

Sionna Therapeutics (SION) Competitors

$5.96 -1.22 (-16.99%)

Closing price 09/18/2026 04:00 PM Eastern

Extended Trading

$6.03 +0.07 (+1.24%)

As of 09/18/2026 07:50 PM Eastern

Compare

SION vs. TYRA, ORIC, AKTS, MGTX, and ALMS

Should you buy Sionna Therapeutics stock or one of its competitors? Sionna Therapeutics's main competitors and comparable companies include Tyra Biosciences (TYRA), Oric Pharmaceuticals (ORIC), Aktis Oncology (AKTS), MeiraGTx (MGTX), and Alumis (ALMS). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Sionna Therapeutics compare to Tyra Biosciences?

Tyra Biosciences (NASDAQ:TYRA) and Sionna Therapeutics (NASDAQ:SION) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two companies based on the strength of their analyst recommendations, institutional ownership, dividends, risk, earnings, profitability, media sentiment and valuation.

Tyra Biosciences presently has a consensus target price of $47.88, indicating a potential upside of 86.07%. Sionna Therapeutics has a consensus target price of $42.33, indicating a potential upside of 610.29%. Given Sionna Therapeutics' higher possible upside, analysts clearly believe Sionna Therapeutics is more favorable than Tyra Biosciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Tyra Biosciences	1 Sell rating(s)	1 Hold rating(s)	11 Buy rating(s)	0 Strong Buy rating(s)	2.77
Sionna Therapeutics	1 Sell rating(s)	11 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

84.1% of Tyra Biosciences shares are owned by institutional investors. 12.5% of Tyra Biosciences shares are owned by company insiders. Comparatively, 5.1% of Sionna Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Tyra Biosciences has a beta of 0.73, indicating that its share price is 27% less volatile than the broader market. Comparatively, Sionna Therapeutics has a beta of 0.89, indicating that its share price is 11% less volatile than the broader market.

Tyra Biosciences is trading at a lower price-to-earnings ratio than Sionna Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Tyra Biosciences	N/A	N/A	-$119.95M	-$2.40	N/A
Sionna Therapeutics	N/A	N/A	-$75.27M	-$2.18	N/A

In the previous week, Sionna Therapeutics had 3 more articles in the media than Tyra Biosciences. MarketBeat recorded 14 mentions for Sionna Therapeutics and 11 mentions for Tyra Biosciences. Tyra Biosciences' average media sentiment score of 0.37 beat Sionna Therapeutics' score of 0.00 indicating that Tyra Biosciences is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Tyra Biosciences	2 Very Positive mention(s)	3 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Neutral
Sionna Therapeutics	1 Very Positive mention(s)	2 Positive mention(s)	7 Neutral mention(s)	2 Negative mention(s)	1 Very Negative mention(s)	Neutral

Sionna Therapeutics' return on equity of -32.94% beat Tyra Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Tyra Biosciences	N/A	-46.39%	-43.07%
Sionna Therapeutics	N/A	-32.94%	-31.08%

Summary

Sionna Therapeutics beats Tyra Biosciences on 8 of the 13 factors compared between the two stocks.

How does Sionna Therapeutics compare to Oric Pharmaceuticals?

Sionna Therapeutics (NASDAQ:SION) and Oric Pharmaceuticals (NASDAQ:ORIC) are both small-cap healthcare companies, but which is the superior investment? We will compare the two companies based on the strength of their earnings, media sentiment, dividends, valuation, analyst recommendations, institutional ownership, risk and profitability.

Sionna Therapeutics has a beta of 0.89, indicating that its stock price is 11% less volatile than the broader market. Comparatively, Oric Pharmaceuticals has a beta of 1, indicating that its stock price has a similar volatility profile to the broader market.

Oric Pharmaceuticals is trading at a lower price-to-earnings ratio than Sionna Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Sionna Therapeutics	N/A	N/A	-$75.27M	-$2.18	N/A
Oric Pharmaceuticals	N/A	N/A	-$129.47M	-$1.35	N/A

95.1% of Oric Pharmaceuticals shares are owned by institutional investors. 5.1% of Sionna Therapeutics shares are owned by company insiders. Comparatively, 5.7% of Oric Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

In the previous week, Sionna Therapeutics had 11 more articles in the media than Oric Pharmaceuticals. MarketBeat recorded 14 mentions for Sionna Therapeutics and 3 mentions for Oric Pharmaceuticals. Oric Pharmaceuticals' average media sentiment score of 0.37 beat Sionna Therapeutics' score of 0.00 indicating that Oric Pharmaceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Sionna Therapeutics	1 Very Positive mention(s)	2 Positive mention(s)	7 Neutral mention(s)	2 Negative mention(s)	1 Very Negative mention(s)	Neutral
Oric Pharmaceuticals	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Neutral

Sionna Therapeutics' return on equity of -32.94% beat Oric Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Sionna Therapeutics	N/A	-32.94%	-31.08%
Oric Pharmaceuticals	N/A	-35.35%	-33.39%

Sionna Therapeutics currently has a consensus target price of $42.33, indicating a potential upside of 610.29%. Oric Pharmaceuticals has a consensus target price of $19.60, indicating a potential upside of 53.24%. Given Sionna Therapeutics' higher possible upside, equities analysts clearly believe Sionna Therapeutics is more favorable than Oric Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Sionna Therapeutics	1 Sell rating(s)	11 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Oric Pharmaceuticals	1 Sell rating(s)	1 Hold rating(s)	12 Buy rating(s)	0 Strong Buy rating(s)	2.79

Summary

Oric Pharmaceuticals beats Sionna Therapeutics on 7 of the 13 factors compared between the two stocks.

How does Sionna Therapeutics compare to Aktis Oncology?

Sionna Therapeutics (NASDAQ:SION) and Aktis Oncology (NASDAQ:AKTS) are both small-cap healthcare companies, but which is the superior investment? We will compare the two businesses based on the strength of their earnings, media sentiment, risk, dividends, profitability, analyst recommendations, institutional ownership and valuation.

Sionna Therapeutics currently has a consensus target price of $42.33, indicating a potential upside of 610.29%. Aktis Oncology has a consensus target price of $35.63, indicating a potential upside of 62.82%. Given Sionna Therapeutics' higher probable upside, research analysts clearly believe Sionna Therapeutics is more favorable than Aktis Oncology.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Sionna Therapeutics	1 Sell rating(s)	11 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Aktis Oncology	1 Sell rating(s)	0 Hold rating(s)	9 Buy rating(s)	1 Strong Buy rating(s)	2.91

28.8% of Aktis Oncology shares are owned by institutional investors. 5.1% of Sionna Therapeutics shares are owned by company insiders. Comparatively, 3.3% of Aktis Oncology shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

In the previous week, Sionna Therapeutics had 12 more articles in the media than Aktis Oncology. MarketBeat recorded 14 mentions for Sionna Therapeutics and 2 mentions for Aktis Oncology. Aktis Oncology's average media sentiment score of 0.86 beat Sionna Therapeutics' score of 0.00 indicating that Aktis Oncology is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Sionna Therapeutics	1 Very Positive mention(s)	2 Positive mention(s)	7 Neutral mention(s)	2 Negative mention(s)	1 Very Negative mention(s)	Neutral
Aktis Oncology	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Aktis Oncology has higher revenue and earnings than Sionna Therapeutics. Aktis Oncology is trading at a lower price-to-earnings ratio than Sionna Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Sionna Therapeutics	N/A	N/A	-$75.27M	-$2.18	N/A
Aktis Oncology	$6.50M	180.93	-$63.73M	-$0.82	N/A

Aktis Oncology's return on equity of 0.00% beat Sionna Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Sionna Therapeutics	N/A	-32.94%	-31.08%
Aktis Oncology	N/A	N/A	N/A

Summary

Aktis Oncology beats Sionna Therapeutics on 10 of the 14 factors compared between the two stocks.

How does Sionna Therapeutics compare to MeiraGTx?

Sionna Therapeutics (NASDAQ:SION) and MeiraGTx (NASDAQ:MGTX) are both small-cap healthcare companies, but which is the superior investment? We will compare the two businesses based on the strength of their dividends, profitability, analyst recommendations, institutional ownership, earnings, valuation, risk and media sentiment.

Sionna Therapeutics has a beta of 0.89, indicating that its stock price is 11% less volatile than the broader market. Comparatively, MeiraGTx has a beta of 1.27, indicating that its stock price is 27% more volatile than the broader market.

Sionna Therapeutics has higher earnings, but lower revenue than MeiraGTx. Sionna Therapeutics is trading at a lower price-to-earnings ratio than MeiraGTx, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Sionna Therapeutics	N/A	N/A	-$75.27M	-$2.18	N/A
MeiraGTx	$81.39M	15.63	-$114.20M	$0.71	18.66

67.5% of MeiraGTx shares are held by institutional investors. 5.1% of Sionna Therapeutics shares are held by company insiders. Comparatively, 7.4% of MeiraGTx shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

In the previous week, Sionna Therapeutics had 12 more articles in the media than MeiraGTx. MarketBeat recorded 14 mentions for Sionna Therapeutics and 2 mentions for MeiraGTx. MeiraGTx's average media sentiment score of 0.83 beat Sionna Therapeutics' score of 0.00 indicating that MeiraGTx is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Sionna Therapeutics	1 Very Positive mention(s)	2 Positive mention(s)	7 Neutral mention(s)	2 Negative mention(s)	1 Very Negative mention(s)	Neutral
MeiraGTx	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Sionna Therapeutics presently has a consensus price target of $42.33, suggesting a potential upside of 610.29%. MeiraGTx has a consensus price target of $26.17, suggesting a potential upside of 97.48%. Given Sionna Therapeutics' higher probable upside, analysts clearly believe Sionna Therapeutics is more favorable than MeiraGTx.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Sionna Therapeutics	1 Sell rating(s)	11 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
MeiraGTx	1 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.75

MeiraGTx has a net margin of 19.87% compared to Sionna Therapeutics' net margin of 0.00%. MeiraGTx's return on equity of 283.85% beat Sionna Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Sionna Therapeutics	N/A	-32.94%	-31.08%
MeiraGTx	19.87%	283.85%	29.39%

Summary

MeiraGTx beats Sionna Therapeutics on 13 of the 16 factors compared between the two stocks.

How does Sionna Therapeutics compare to Alumis?

Alumis (NASDAQ:ALMS) and Sionna Therapeutics (NASDAQ:SION) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two businesses based on the strength of their analyst recommendations, dividends, institutional ownership, profitability, media sentiment, risk, valuation and earnings.

Alumis has a beta of -0.81, indicating that its stock price is 181% less volatile than the broader market. Comparatively, Sionna Therapeutics has a beta of 0.89, indicating that its stock price is 11% less volatile than the broader market.

In the previous week, Sionna Therapeutics had 8 more articles in the media than Alumis. MarketBeat recorded 14 mentions for Sionna Therapeutics and 6 mentions for Alumis. Alumis' average media sentiment score of 0.41 beat Sionna Therapeutics' score of 0.00 indicating that Alumis is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Alumis	1 Very Positive mention(s)	0 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Sionna Therapeutics	1 Very Positive mention(s)	2 Positive mention(s)	7 Neutral mention(s)	2 Negative mention(s)	1 Very Negative mention(s)	Neutral

Sionna Therapeutics has a net margin of 0.00% compared to Alumis' net margin of -5,933.46%. Sionna Therapeutics' return on equity of -32.94% beat Alumis' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Alumis	-5,933.46%	-93.15%	-74.50%
Sionna Therapeutics	N/A	-32.94%	-31.08%

Alumis currently has a consensus price target of $33.27, suggesting a potential upside of 328.22%. Sionna Therapeutics has a consensus price target of $42.33, suggesting a potential upside of 610.29%. Given Sionna Therapeutics' higher probable upside, analysts clearly believe Sionna Therapeutics is more favorable than Alumis.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Alumis	1 Sell rating(s)	1 Hold rating(s)	10 Buy rating(s)	1 Strong Buy rating(s)	2.85
Sionna Therapeutics	1 Sell rating(s)	11 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Sionna Therapeutics has lower revenue, but higher earnings than Alumis. Sionna Therapeutics is trading at a lower price-to-earnings ratio than Alumis, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Alumis	$24.05M	41.82	-$243.32M	-$3.86	N/A
Sionna Therapeutics	N/A	N/A	-$75.27M	-$2.18	N/A

Summary

Sionna Therapeutics beats Alumis on 8 of the 14 factors compared between the two stocks.

Get Sionna Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding SION and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

SION vs. The Competition

Export

Metric	Sionna Therapeutics	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$269.46M	$3.90B	$7.24B	$13.19B
Dividend Yield	N/A	3.64%	2.57%	12.81%
P/E Ratio	-2.73	14.23	275.49	25.40
Price / Sales	N/A	1,419.61	646.01	89.45
Price / Cash	N/A	108.90	76.25	51.42
Price / Book	0.87	15.45	10.46	6.33
Net Income	-$75.27M	-$22.86M	$3.49B	$358.33M
7 Day Performance	-24.08%	-1.21%	0.59%	1.12%
1 Month Performance	7.97%	-3.29%	-1.74%	-2.39%
1 Year Performance	-74.24%	37.74%	18.13%	5.35%

Sionna Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
SION Sionna Therapeutics	3.1491 of 5 stars	$5.96 -17.0%	$42.33 +610.3%	-74.2%	$269.46M	N/A	N/A	59	Analyst Forecast High Trading Volume
TYRA Tyra Biosciences	3.3933 of 5 stars	$23.54 +7.0%	$47.88 +103.4%	+105.8%	$1.31B	N/A	N/A	20	Gap Down High Trading Volume
ORIC Oric Pharmaceuticals	2.3248 of 5 stars	$12.07 -3.4%	$19.60 +62.4%	+21.1%	$1.30B	N/A	N/A	80
AKTS Aktis Oncology	3.0429 of 5 stars	$23.94 -0.5%	$35.63 +48.8%	N/A	$1.29B	$6.50M	N/A	76
MGTX MeiraGTx	3.9146 of 5 stars	$12.85 -3.1%	$26.17 +103.6%	+75.3%	$1.27B	$81.39M	18.10	300

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:SION) was last updated on 9/20/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Sionna Therapeutics (SION) Competitors

SION vs. TYRA, ORIC, AKTS, MGTX, and ALMS

How does Sionna Therapeutics compare to Tyra Biosciences?

Summary

How does Sionna Therapeutics compare to Oric Pharmaceuticals?

Summary

How does Sionna Therapeutics compare to Aktis Oncology?

Summary

How does Sionna Therapeutics compare to MeiraGTx?

Summary

How does Sionna Therapeutics compare to Alumis?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

SION vs. The Competition

Sionna Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Sionna Therapeutics (SION) Competitors

SION vs. TYRA, ORIC, AKTS, MGTX, and ALMS

How does Sionna Therapeutics compare to Tyra Biosciences?

Do analysts recommend TYRA or SION?

Do insiders and institutionals believe in TYRA or SION?

Which has more risk and volatility, TYRA or SION?

Which has better earnings & valuation, TYRA or SION?

Does the media prefer TYRA or SION?

Is TYRA or SION more profitable?

Summary

How does Sionna Therapeutics compare to Oric Pharmaceuticals?

Which has more risk and volatility, SION or ORIC?

Which has stronger earnings and valuation, SION or ORIC?

Do insiders & institutionals hold more shares of SION or ORIC?

Does the media favor SION or ORIC?

Is SION or ORIC more profitable?

Do analysts rate SION or ORIC?

Summary

How does Sionna Therapeutics compare to Aktis Oncology?

Do analysts rate SION or AKTS?

Do insiders & institutionals hold more shares of SION or AKTS?

Does the media prefer SION or AKTS?

Which has higher earnings & valuation, SION or AKTS?

Is SION or AKTS more profitable?

Summary

How does Sionna Therapeutics compare to MeiraGTx?

Which has more volatility and risk, SION or MGTX?

Which has stronger earnings & valuation, SION or MGTX?

Do insiders and institutionals have more ownership in SION or MGTX?

Does the media refer more to SION or MGTX?

Do analysts rate SION or MGTX?

Is SION or MGTX more profitable?

Summary

How does Sionna Therapeutics compare to Alumis?

Which has more volatility & risk, ALMS or SION?

Does the media favor ALMS or SION?

Is ALMS or SION more profitable?

Do analysts prefer ALMS or SION?

Which has higher valuation & earnings, ALMS or SION?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

SION vs. The Competition

Sionna Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools